Pediatric Infectious Disease

Register      Login

VOLUME 3 , ISSUE 1 ( January-March, 2021 ) > List of Articles


Use of Antifungals Other Than Amphotericin B for Invasive Fungal Infections in Neonates and Children

Citation Information : Use of Antifungals Other Than Amphotericin B for Invasive Fungal Infections in Neonates and Children. Pediatr Inf Dis 2021; 3 (1):38-42.

DOI: 10.5005/jp-journals-10081-1256

License: CC BY-NC 4.0

Published Online: 01-03-2021

Copyright Statement:  Copyright © 2021; The Author(s).


Antifungal therapy for neonates, children, and adolescents, especially in those with primary or secondary immunodeficiencies having invasive fungal infections, is possible today due to the advent of newer antifungals. Studies of antifungals in the pediatric age-group are limited to those for cutaneous fungal infections. Although there are a few studies on the pharmacokinetics and safety, these drugs are used off-label, and most dosage recommendations are extrapolated from the adult data. A review of the use of antifungals other than amphotericin B for treatment of invasive fungal infections in pediatrics is the focus of this article.

PDF Share
  1. Unni JC. Review of amphotericin B for invasive fungal infections in neonates and children. Pediatr Infect Dis 2020. DOI: 10.5005/jp-journals-10081-1240.
  2. Lestner JM, Smith BP, Cohen-Wolkowiez M, et al. Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective. Br J Clin Pharmacol 2013;75(6):1381–1395. DOI: 10.1111/bcp.12025.
  3. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999;12(4):501–517. DOI: 10.1128/CMR.12.4.501.
  4. Johnson KC, Barone JG. Management of obstructive fungal pyelonephritis in infants. Urology 2006;67(2):424.e7–424.e9. DOI: 10.1016/j.urology.2005.09.017.
  5. Schwarz P, Janbon G, Dromer F, et al. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans. Antimicrob Agents Chemother 2007;51(1):383–385. DOI: 10.1128/AAC.00446-06.
  6. Liu Y, Kang M, Ye H, et al. Analysis on clinical characteristics and drug resistance of Candida parapsilosis bloodstream infections in west china hospital, China, from 2012 to 2015. Mycol Med 2018;28(1):222–226. DOI: 10.1016/j.mycmed.2017.05.001.
  7. Merry M, Boulware DR. Cryptococcal meningitis treatment strategies affected by the explosive cost of flucytosine in the United States: a cost-effectiveness analysis. Clin Infect Dis 2016;62(12):1564–1568. DOI: 10.1093/cid/ciw151.
  8. Benjamin DK, Stoll BJ, Fanaroff AA, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18-22 months. Pediatrics 2006;117(1):84–92. DOI: 10.1542/peds.2004-2292.
  9. Vermes A, Guchelaar H, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000;46(2):171–179. DOI: 10.1093/jac/46.2.171.
  10. Luparia M, Landi F, Mesini A, et al. Fungal ecology in a tertiary neonatal intensive care unit after 16 years of routine fluconazole prophylaxis: no emergence of native fluconazole-resistant strains. Am J Perinatol 2019;36(S02):S126–S133. DOI: 10.1055/s-0039-1691808.
  11. Che D, Zhou H, Li T, et al. Duration and intensity of fluconazole for prophylaxis in preterm neonates: a Meta-analysis of randomized controlled trials. BMC Infect Dis 2016;16(1):312. DOI: 10.1186/s12879-016-1645-5.
  12. Bafeltowska JJ, Buszman E. Pharmacokinetics of fluconazole in the cerebrospinal fluid of children with hydrocephalus. Chemotherapy 2005;51(6):370–376. DOI: 10.1159/000088965.
  13. Manosuthi W, Chetchotisakd P, Nolen TL, et al. BAMSG 3-01 study team. monitoring and impact of fluconazole Serum and cerebrospinal fluid concentration in HIV-associated cryptococcal meningitis-infected patients. HIV Med 2010;11(4):276–281. DOI: 10.1111/j.1468-1293.2009.00778.x.
  14. Fisher JF, Sobel JD, Kauffman CA, et al. Candida urinary tract infections — treatment. Clin Infect Dis 2011;52(Suppl_6):S457–S466. DOI: 10.1093/cid/cir112.
  15. Vazquez L. Antifungal prophylaxis in immunocompromised patients. Mediterr J Hematol Infect Dis 2016;8(1):e2016040. DOI: 10.4084/MJHID.2016.040.
  16. Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect 2018;24(Suppl 1):e1–e38. DOI: 10.1016/j.cmi.2018.01.002.
  17. Tsai M, Hsu J, Yang L, et al. Candidemia due to uncommon candida species in children: new threat and impacts on outcomes. Sci Rep 2018;8(1):15239. DOI: 10.1038/s41598-018-33662-x.
  18. Garcia-Rubio R, Cuenca-Estrella M, Mellado E. Triazole resistance in Aspergillus species: an emerging problem. Drugs 2017;77(6):599–613. DOI: 10.1007/s40265-017-0714-4.
  19. Sharpe AR, Lagrou K, Meis JF, et al. On behalf of the ISHAM/ECMM Aspergillus resistance surveillance working. group. triazole resistance surveillance in Aspergillus fumigatus. Med Mycol 2018;56(suppl_1):S83–S92. DOI: 10.1093/mmy/myx144.
  20. Döring M, Blume O, Haufe S, et al. Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation. Eur J Clin Microbiol Infect Dis 2014;33(4):629–631. DOI: 10.1007/s10096-013-1998-2.
  21. Jenks JD, Reed SL, Seidel D, et al. Rare mould infections caused by mucorales, lomentospora prolificans and fusarium, in San Diego, CA: the role of antifungal combination therapy. Int J Antimicrob Agents 2018;52(5):706–712. DOI: 10.1016/j.ijantimicag.2018.08.005.
  22. Almannai M, Imran H, Estrada B, et al. Successful treatment of rhino-orbital mucormycosis with posaconazole and hyperbaric oxygen therapy. Pediatr Hematol Oncol 2013;30(3):184–186. DOI: 10.3109/08880018.2013.770587.
  23. Page 2nd RL, Schwiesow J, Hilts A. Posaconazole as salvage therapy in a patient with disseminated zygomycosis: case report and review of the literature. Pharmacotherapy 2007;27(2):290–298. DOI: 10.1592/phco.27.2.290.
  24. Taj-Aldeen SJ, Rammaert B, Gamaletsou M, et al. O, international osteoarticular mycoses consortium. osteoarticular infections caused by non-aspergillus filamentous fungi in adult and pediatric patients: a systematic review. Medicine (Baltimore) 2015;94(50):e2078. DOI: 10.1097/MD.000000000000207.
  25. Sienkiewicz BM, Łapiński L, Wiela-Hojeńska A. Comparison of clinical pharmacology of voriconazole and posaconazole. Contemp Oncol (Pozn) 2016;20(5):365–373. DOI: 10.5114/wo.2016.64594.
  26. Moore JN, Healy JR, Kraft WK. Pharmacologic and clinical evaluation of posaconazole. Expert Rev Clin Pharmaco 2015;8(3):321–334. DOI: 10.1586/17512433.2015.1034689.
  27. Perlin DS. Echinocandin resistance in Candida. Clin Infect Dis 2015;61(Suppl 6):S612–S617. DOI: 10.1093/cid/civ791.
  28. Pfieffer CD, Gracia-Effron G, Zaas AK, et al. Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol 2010;48(7):2373–2380. DOI: 10.1128/JCM.02390-09.
  29. Papp C, Kocsis K, Tóth R, et al. Echinocandin-induced microevolution of Candida parapsilosis influences virulence and abiotic stress tolerance. mSphere 2014;3(6):e00547-18.
  30. Caudle KE, Inger AG, Butler DR, et al. Echinocandin use in the neonatal intensive care unit. Ann Pharmacother 2012;46(1):108–116. DOI: 10.1345/aph.1Q346.
  31. Hope WW, Smith BP, Arrieta A, et al. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother 2010;54(6):2633–2637. DOI: 10.1128/AAC.01679-09.
  32. Pammi M, Holland L, Butler G, et al. Candida parapsilosis is a significant neonatal pathogen: a systematic review and meta-analysis. Pediatr Infect Dis J 2013;32(5):e206–e216. DOI: 10.1097/INF.0b013e3182863a1c.
  33. Warn PA, Livermore J, Howard S, et al. Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach. Antimicrob Agents Chemother 2012;56(2):708–714. DOI: 10.1128/AAC.05826-11.
  34. VandenBussche HL, Loo DAV. A clinical review of echinocandins in pediatric patients. Ann Pharmacother 2010;44(1):166–177. DOI: 10.1345/aph.1M139.
  35. Ullmann S, Meert AJ, Paesmans L, et al. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European organisation for research and treatment of cancer study. Bone Marrow Transplant 2010;45(7):1227–1233. DOI: 10.1038/bmt.2009.334.
  36. Mikulska M, Viscoli C. Current role of echinocandins in the management of invasive aspergillosis. Curr Infect Dis Rep 2011;13(6):517–527. DOI: 10.1007/s11908-011-0216-6.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.